Fecal Microbiota Transplantation: Is It Safe?

Seon-Young Park; Geom Seog Seo

doi:10.5946/ce.2021.072

Articles

Page Path: HOME > Clin Endosc > Volume 54(2); 2021 > Article

Focused Review Series: Future Perspectives of Fecal Microbiota Transplatation Fecal Microbiota Transplantation: Is It Safe?: Seon-Young Park¹, Geom Seog Seo²; Clinical Endoscopy 2021;54(2):157-160.
DOI: https://doi.org/10.5946/ce.2021.072
Published online: March 30, 2021

¹Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea

²Department of Internal Medicine, Digestive Disease Research Institute, Wonkwang University College of Medicine, Iksan, Korea

Correspondence: Goem Seog Seo Department of Internal Medicine, Digestive Disease Research Institute, Wonkwang University College of Medicine, 460 Iksan-daero, Iksan 54538, Korea Tel: +82-63-859-2565, Fax: +82-63-855-2025, E-mail: medsgs@wku.ac.kr

It is the invited review article.

• Received: February 5, 2021 • Revised: March 11, 2021 • Accepted: March 12, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,483 Views
139 Download
37 Web of Science
38 Crossref
39 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
ADVERSE EVENTS ASSOCIATED WITH FMT
SAFETY ISSUE IN HIGH-RISK PATIENTS
SAFETY OF FMT IN THE CORONAVIRUS DISEASE 2019 ERA
HOW TO AVOID HARMFUL EFFECTS OF FMT
CONCLUSIONS
NOTES
REFERENCES

Abstract

Fecal microbiota transplantation (FMT) is an accepted procedure for the management of recurrent Clostridioides difficile infections. FMT is generally considered safe and well-tolerated - even in high-risk patients. Most short-term risks are mild and known to be associated with delivery methods. Long-term side effects have not been established, and no signs of harm have been found to date. However, causality for several microbiome-associated diseases has to be established. Even though FMT is generally considered safe with strict donor screening, serious adverse events have been recently associated with the FMT product from the stool bank, where screening for multi-drug resistant organisms is not included in protocols. Here, we discuss the adverse events associated with FMT and safety issues.
Keywords: Adverse events; Fecal microbiota transplantation; Safety

INTRODUCTION

Fecal microbiota transplantation (FMT) is an accepted procedure for managing recurrent Clostridioides difficile infection (CDI). FMT is generally considered safe and well-tolerated - even in high-risk patients. Most short-term risks are mild and known to be associated with delivery methods. Long-term side effects have not been established, and no signs of harm have been found to date. However, causality for several microbiome-disease associations should be established.

In this review, we discuss the adverse events associated with FMT, as well as its safety, based on clinical studies and systematic reviews on treatment for CDI.

ADVERSE EVENTS ASSOCIATED WITH FMT

FMT is usually considered safe, and the common side effects are minor adverse events, including transient diarrhea, abdominal cramps or pain, low-grade fever, bloating, flatulence, and constipation (Table 1) [1]. However, we should consider the possible uncommon severe side effects following FMT.

Adverse events related to stool bank

Among the adverse events, the risk of infection transmission after FMT has been a concern, especially after an Food and Drug Administration (FDA) report of two cases of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) infection (one death) and six cases of Shiga toxin-producing E. coli infection (two subsequent deaths), probably transmitted through the donor stool [2]. The donated stool was manufactured into capsules without ESBL screening. In response, the FDA created a national alert and mandated additional screening for ESBLs [3]. In addition to the short-term risk of infection transmission, a recent prospective registry study [4] suggested that 4% of participants developed new infectious diseases between 1 and 6 months; some were related to FMT, but others were not.

Adverse events related to delivery routes

The delivery method of FMT is another concern related to adverse events. Most short-term risks are attributable to the delivery method rather than FMT itself. A systematic review suggested that FMT treatment via the upper gastrointestinal route was associated with higher incidence rates of adverse events (43.9%) than FMT treatment via the lower gastrointestinal tract (20.6%) [5]. Fatal aspiration pneumonia was reported as a severe complication of FMT administered by a nasoduodenal tube [6]. However, there was no general agreement on the better route for the administration of FMT. Even though there is no need for bowel cleaning when administering FMT via the nasoduodenal or nasojejunal route, clinicians need to consider the increased risk of aspiration pneumonia or pneumonitis, especially in patients with neurologic problems or bedridden patients. Moreover, lower gastrointestinal delivery of FMT is known to be more effective in patients with recurrent CDI [7]. Therefore, the optimum route should be selected based on the nature and intensity of the disease, the patient’s age and preference, hospitalization, donor selection, psychological and economic status of the patients, and the need for subsequent FMTs [8].

Long-term adverse events associated with donor microbe engraftment

Previous studies suggested the long-term effect of donor microbe engraftment, including host susceptibility to diseases, including obesity and immune-mediated disorders, such as immune thrombocytopenia, rheumatoid arthritis, and inflammatory bowel disease [9-12]. In a prospective registry, two patients were newly diagnosed with irritable bowel syndrome, and two patients were newly diagnosed with ulcerative colitis, among the 156 participants who underwent a 6-month follow-up after FMT [4].

SAFETY ISSUE IN HIGH-RISK PATIENTS

The safety of FMT in high-risk patients has not been established, as almost all FMT trials excluded those patients. A recent systematic review of 44 studies on FMT for CDI showed an 88% treatment success rate in 303 immunocompromised patients (almost all patients used immunosuppressive medication), [13] of which 2 patients died, 2 patients had colectomies, 5 patients had treatment-related infections, and 10 patients were subsequently hospitalized. Based on the findings of that study, FMT in immunocompromised patients seems to have comparable safety to that in immunocompetent patients [13]. However, the transmission of live microorganisms to recipients with underlying illnesses presents a greater potential risk [14,15]. For example, clinicians should consider the possible transmission of the Epstein-Barr virus and cytomegalovirus from donors in immunosuppressed FMT recipients, for which recent guidelines recommend additional donor screening [16]. Several risks are mitigated by implementing a careful selection and screening process for prospective donors. Luo et al. suggested a higher incidence of adverse events in high-risk patients, including immunocompromised patients, patients with inflammatory bowel disease (IBD), and patients with fulminant colitis [17]. Particularly, clinicians should consider the risk of IBD flare-ups in patients with IBD. Another systematic review of FMT for the treatment of IBD showed bothersome serious side effects: 7% of FMT participants, compared with 5% of controls, had severe adverse events (relative risk, 1.4; 95% confidence interval, 0.5-3.6) [18]. However, this should be interpreted with caution, because the adverse event reports were not standardized. In solid-organ transplant recipients who underwent FMT for the treatment of CDI, adverse events occurred in 22.3%, and relatively mild adverse events, such as nausea, abdominal pain, diarrhea, and severe adverse events occurred in 3.2% of patients, suggesting that FMT is safe in solid-organ transplant recipients [19]. Table 2 summarizes the safety of FMT in high-risk patients.

SAFETY OF FMT IN THE CORONAVIRUS DISEASE 2019 ERA

With the outbreak of the coronavirus disease 2019 (COVID-19), several centers have decreased the volume of routine diagnostic or elective procedures to avoid potential transmission of the virus. Several studies have reported a longer excretion of severe acute respiratory syndrome coronavirus 2 through feces than through the nasopharyngeal route [21]. Therefore, several FMT centers and stool banks have suspended the active performance of FMT and the recruitment of FMT donors. Recently, the FDA recommended only FMT products generated from donated stool before December 2019 [21]. However, FMT plays a major role in the management of recurrent CDI and cannot be postponed, especially in patients with life-threatening conditions. Therefore, during this COVID-19 pandemic, FMT should be considered a nonpostponable treatment modality, especially in patients with severe and/or recurrent CDI. A recent study demonstrated the possible application of FMT in patients with recurrent CDI during the COVID-19 pandemic by adopting specific changes in the workflow [22]. Recent guidelines have proposed a very strict workflow of stool donation, in which positivity of polymerase chain reaction for nasopharyngeal swabs, stool, and/or Immunoglobulin M serology should be an absolute contraindication for donation [21].

HOW TO AVOID HARMFUL EFFECTS OF FMT

Even though FMT is generally considered safe, a severe adverse event has been reported to be associated with its product manufactured under a protocol that did not involve screening for multi-drug resistant organisms. Therefore, rigorous donor screening and testing should be mandated to minimize the risks of FMT, especially during the COVID-19 pandemic.

CONCLUSIONS

FMT is generally considered safe, and a recent study suggested that it is well-tolerated in high-risk patients. Rigorous donor screening and testing should be mandated to minimize the risk of FMT, especially during the COVID-19 pandemic.

NOTES

Conflicts of Interest: The authors have no potential conflicts of interest.

Funding

None.

Table 1.

Adverse Events in Patients who Underwent Fecal Microbiota Transplantation

Short-term adverse events	Long-term adverse events
Bloating/Spasm	Obesity
Gaseousness	Immune-mediated disorders
Diarrhea	Immune thrombocytopenia
Irregular bowel habit	Rheumatoid arthritis
Irritable bowel syndrome	Inflammatory bowel disease
Constipation	Irritable bowel syndrome
Abdominal pain, tenderness
Fever
Nausea
Aggravation of inflammatory bowel disease
Gram negative bacteremia
Bowel perforation
Belching
Death
Hematochezia

Table 2.

Safety of Fecal Microbiota Transplatation in High-Risk Patients

Participants	Article types	Adverse events
Immunocompromised host	Systematic review (303 patients) [13]	Deaths (n=2), Colectomy (n=2), Bacteremia or infection (n=5), hospitalization (n=10), unspecificed life threatening complica- tion (n=7), flare-up of IBD (n=7)
Ulcerative colitis (mild to moderate)	Meta-analysis (4 studies, 277 patients) [18]	Serious adverse events: 7% of FMT participants vs. 5% of controls (RR, 1.4; 95% CI, 0.5-3.6)
	Meta-analysis (11 studies) [20]	Overall adverse events (95% CI): 36.9% (21.5–55.6)
Crohn’s disease	Meta-analysis (3 studies) [20]	Overall adverse events (95% CI): 5.8% (1.2–23.5)
Solid-organ transplantation recipients	Retrospective study (94 patients) [19]	Overall FMT related adverse events: 22.3%
Solid-organ transplantation recipients	Retrospective study (94 patients) [19]	Serious FMT related adverse events: 3.2%

CI, confidence interval; IBD, inflammatory bowel disease; FMT, fecal microbiota transplantation; RR, relative risk

REFERENCES

1. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One 2016;11:e0161174.Article PubMed PMC
2. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019;381:2043–2050.Article PubMed
3. Merrick B, Allen L, Masirah M Zain N, Forbes B, Shawcross DL, Goldenberg SD. Regulation, risk and safety of faecal microbiota transplant. Infection Prevention in Practice 2020;2:100069.Article PubMed PMC
4. Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the fmt national registry. Gastroenterology 2021;160:183–192.e3.Article PubMed PMC
5. Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1179–1192.Article PubMed
6. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 2015;61:136–137.Article PubMed
7. Furuya-Kanamori L, Doi SAR, Paterson DL, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol 2017;51:145–150.Article PubMed
8. Gulati M, Singh SK, Corrie L, Kaur IP, Chandwani L. Delivery routes for faecal microbiota transplants: available, anticipated and aspired. Pharmacol Res 2020;159:104954.Article PubMed
9. Smillie CS, Sauk J, Gevers D, et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 2018;23:229–240.e5.Article PubMed PMC
10. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–109.e6.Article PubMed
11. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017;389:1218–1228.Article PubMed
12. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:1079–1087.Article PubMed
13. Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018;2018:1394379.Article PubMed PMC
14. Alrabaa S, Jariwala R, Zeitler K, Montero J. Fecal microbiota transplantation outcomes in immunocompetent and immunocompromised patients: a single-center experience. Transpl Infect Dis 2017;19.Article
15. Lin SC, Alonso CD, Moss AC. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature. Transpl Infect Dis 2018;20:e12967.Article PubMed
16. Mullish BH, Quraishi MN, Segal JP, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2018;67:1920–1941.Article PubMed
17. Luo Y, Tixier EN, Grinspan AM. Fecal microbiota transplantation for Clostridioides difficile in high-risk older adults is associated with early recurrence. Dig Dis Sci 2020;65:3647–3651.Article PubMed
18. Imdad A, Nicholson MR, Tanner-Smith EE, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018;11:CD012774.Article PubMed PMC
19. Cheng Y-W, Phelps E, Ganapini V, et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am J Transplant 2019;19:501–511.Article PubMed PMC
20. Caldeira L de F, Borba HH, Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Fecal microbiota transplantation in inflammatory bowel disease patients: a systematic review and meta-analysis. PLoS One 2020;15:e0238910.Article PubMed PMC
21. Ianiro G, Mullish BH, Kelly CR, et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut 2020;69:1555–1563.Article PubMed PMC
22. Ianiro G, Bibbò S, Masucci L, et al. Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: a prospective cohort study. Dig Liver Dis 2020;52:1390–1395.Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function
Sophie Irwin, Andrea Chupina Estrada, Becca Nelson, Ashlen Bullock, Berkeley Limketkai, Wendy Ho, Susan Acton, Laurent Chesnel, Hon Wai Koon
Frontiers in Microbiology.2024;[Epub] CrossRef
Metabolic model predictions enable targeted microbiome manipulation through precision prebiotics
Georgios Marinos, Inga K. Hamerich, Reena Debray, Nancy Obeng, Carola Petersen, Jan Taubenheim, Johannes Zimmermann, Dana Blackburn, Buck S. Samuel, Katja Dierking, Andre Franke, Matthias Laudes, Silvio Waschina, Hinrich Schulenburg, Christoph Kaleta, Pau
Microbiology Spectrum.2024;[Epub] CrossRef
Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update
Tousif Ahmed Hediyal, C. Vichitra, Nikhilesh Anand, Mahendran Bhaskaran, Saeefh M. Essa, Pravir Kumar, M. Walid Qoronfleh, Mohammed Akbar, Ruchika Kaul-Ghanekar, Arehally M. Mahalakshmi, Jian Yang, Byoung-Joon Song, Tanya M. Monaghan, Meena Kishore Sakhar
Frontiers in Immunology.2024;[Epub] CrossRef
Past, present, and future of microbiome-based therapies
Pilar Manrique, Ignacio Montero, Marta Fernandez-Gosende, Noelia Martinez, Claudio Hidalgo Cantabrana, David Rios-Covian
Microbiome Research Reports.2024;[Epub] CrossRef
Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation
Giovanna Yazmín Arteaga-Muller, Samantha Flores-Treviño, Paola Bocanegra-Ibarias, Diana Robles-Espino, Elvira Garza-González, Graciela Catalina Fabela-Valdez, Adrián Camacho-Ortiz
Nutrients.2024; 16(8): 1109. CrossRef
The Importance of Microbiota and Fecal Microbiota Transplantation in Pancreatic Disorders
Adrian Boicean, Cristian Ichim, Samuel Bogdan Todor, Paula Anderco, Mirela Livia Popa
Diagnostics.2024; 14(9): 861. CrossRef
Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
Coco M. Fuhri Snethlage, Douwe de Wit, Koen Wortelboer, Elena Rampanelli, Nordin M. J. Hanssen, Max Nieuwdorp
Immunological Reviews.2024;[Epub] CrossRef
Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers
Monica Profir, Oana Alexandra Roşu, Sanda Maria Creţoiu, Bogdan Severus Gaspar
Microorganisms.2024; 12(5): 955. CrossRef
Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease
Keiichi Sumida, Joseph F. Pierre, Melana Yuzefpolskaya, Paolo C. Colombo, Ryan T. Demmer, Csaba P. Kovesdy
Seminars in Nephrology.2023; 43(2): 151408. CrossRef
Fecal microbiota transplantation in childhood: past, present, and future
Xu Gu, Zhao-Hong Chen, Shu-Cheng Zhang
World Journal of Pediatrics.2023; 19(9): 813. CrossRef
Bacteria-driven bio-therapy: From fundamental studies to clinical trials
Yuxuan Yu, Sicen Lin, Zhichao Chen, Bin Qin, Zhonggui He, Maosheng Cheng, Mengchi Sun, Jin Sun
Nano Today.2023; 48: 101731. CrossRef
Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease
Gudimetla Susmitha, Rahul Kumar
Neuropharmacology.2023; 229: 109478. CrossRef
Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model
Perezimor Etifa, César Rodríguez, Céline Harmanus, Ingrid M. J. G. Sanders, Igor A. Sidorov, Olufunmilayo A. Mohammed, Emily Savage, Andrew R. Timms, Jane Freeman, Wiep Klaas Smits, Mark H. Wilcox, Simon D. Baines
Antibiotics.2023; 12(3): 435. CrossRef
Discovery of Lactomodulin, a Unique Microbiome-Derived Peptide That Exhibits Dual Anti-Inflammatory and Antimicrobial Activity against Multidrug-Resistant Pathogens
Walaa K. Mousa, Rose Ghemrawi, Tareq Abu-Izneid, Azza Ramadan, Farah Al-Marzooq
International Journal of Molecular Sciences.2023; 24(8): 6901. CrossRef
The Influence of Gut Microbial Species on Diabetes Mellitus
Raghad Khalid AL-Ishaq, Samson Mathews Samuel, Dietrich Büsselberg
International Journal of Molecular Sciences.2023; 24(9): 8118. CrossRef
Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome
Brian Bicknell, Ann Liebert, Thomas Borody, Geoffrey Herkes, Craig McLachlan, Hosen Kiat
International Journal of Molecular Sciences.2023; 24(11): 9577. CrossRef
Gut Microbiome Transplants and Their Health Impacts across Species
Benjamin H. Levine, Jessica M. Hoffman
Microorganisms.2023; 11(6): 1488. CrossRef
Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
Anne J. Gonzales-Luna, Travis J. Carlson, Kevin W. Garey
Gut Microbes.2023;[Epub] CrossRef
The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis
Farzaneh Fakharian, Siva Thirugnanam, David A. Welsh, Woong-Ki Kim, Jay Rappaport, Kyle Bittinger, Namita Rout
Microorganisms.2023; 11(7): 1849. CrossRef
Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice
Laura Rossier, Christoph Matter, Emanuel Burri, Tatiana Galperine, Petr Hrúz, Pascal Juillerat, Alain Schoepfer, Stephan R. Vavricka, Nadine Zahnd, Natalie Décosterd, Frank Seibold
Swiss Medical Weekly.2023; 153(8): 40100. CrossRef
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
Muthukumaran Jayachandran, Shen Qu
Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1189. CrossRef
Fecal Microbiota Transplantation in Liver Cirrhosis
Adrian Boicean, Victoria Birlutiu, Cristian Ichim, Olga Brusnic, Danusia Maria Onișor
Biomedicines.2023; 11(11): 2930. CrossRef
Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Parnian Jamshidi, Yeganeh Farsi, Zahra Nariman, Mohammad Reza Hatamnejad, Benyamin Mohammadzadeh, Hossein Akbarialiabad, Mohammad Javad Nasiri, Leonardo A. Sechi
International Journal of Molecular Sciences.2023; 24(19): 14562. CrossRef
Gut microbiota of Suncus murinus, a naturally obesity-resistant animal, improves the ecological diversity of the gut microbiota in high-fat-diet-induced obese mice
Mingshou Zhang, Ting Yang, Rujia Li, Ke Ren, Jun Li, Maozhang He, Juefei Chen, Shuang-Qin Yi, Farah Al-Marzooq
PLOS ONE.2023; 18(11): e0293213. CrossRef
New Awareness of the Interplay Between the Gut Microbiota and Circadian Rhythms
Xiaoxiao Pang, Long Chen, Guoxin Xu
Polish Journal of Microbiology.2023; 72(4): 355. CrossRef
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea
Tae-Geun Gweon, Yoo Jin Lee, Kyeong Ok Kim, Sung Kyun Yim, Jae Seung Soh, Seung Young Kim, Jae Jun Park, Seung Yong Shin, Tae Hee Lee, Chang Hwan Choi, Young-Seok Cho, Dongeun Yong, Jin-Won Chung, Kwang Jae Lee, Oh Young Lee, Myung-Gyu Choi, Miyoung Choi
Journal of Neurogastroenterology and Motility.2022; 28(1): 28. CrossRef
A Potential Synbiotic Strategy for the Prevention of Type 2 Diabetes: Lactobacillus paracasei JY062 and Exopolysaccharide Isolated from Lactobacillus plantarum JY039
Jiayuan Zhao, Lihan Wang, Shasha Cheng, Yu Zhang, Mo Yang, Ruxue Fang, Hongxuan Li, Chaoxin Man, Yujun Jiang
Nutrients.2022; 14(2): 377. CrossRef
Linking circadian rhythms to microbiome-gut-brain axis in aging-associated neurodegenerative diseases
Wai-Yin Cheng, Yuen-Shan Ho, Raymond Chuen-Chung Chang
Ageing Research Reviews.2022; 78: 101620. CrossRef
Modulating the Gut Microbiota as a Therapeutic Intervention for Alzheimer’s Disease
Mingli Liu, Ping Zhong
Indian Journal of Microbiology.2022; 62(4): 494. CrossRef
Role of Microbiota in Viral Infections and Pathological Progression
Taketoshi Mizutani, Aya Ishizaka, Michiko Koga, Takeya Tsutsumi, Hiroshi Yotsuyanagi
Viruses.2022; 14(5): 950. CrossRef
Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Cátia Almeida, Rita Oliveira, Pilar Baylina, Rúben Fernandes, Fábio G. Teixeira, Pedro Barata
Biomedicines.2022; 10(11): 2742. CrossRef
Consortium of Indigenous Fecal Bacteria in the Treatment of Metabolic Syndrome
Elena Ermolenko, Marina Kotyleva, Anna Kotrova, Sergey Tichonov, Nadezhda Lavrenova, Lyubov Voropaeva, Yulia Topalova, Alena Karaseva, Daniil Azarov, Konstantin Ermolenko, Dmitrii Druzhininskii, Alexander Dmitriev, Alexander Shishkin, Alexander Suvorov
Microorganisms.2022; 10(8): 1574. CrossRef
Machine learning on the road to unlocking microbiota’s potential for boosting immune checkpoint therapy
Szymon Wojciechowski, Monika Majchrzak-Górecka, Paweł Biernat, Krzysztof Odrzywołek, Łukasz Pruss, Konrad Zych, Jan Majta, Kaja Milanowska-Zabel
International Journal of Medical Microbiology.2022; 312(7): 151560. CrossRef
Exploring the Connection Between the Gut Microbiome and Parkinson’s Disease Symptom Progression and Pathology: Implications for Supplementary Treatment Options
Dennis G. Chan, Katelyn Ventura, Ally Villeneuve, Paul Du Bois, Matthew R. Holahan
Journal of Parkinson's Disease.2022; 12(8): 2339. CrossRef
Microbiome Therapeutics for Food Allergy
Diana A. Chernikova, Matthew Y. Zhao, Jonathan P. Jacobs
Nutrients.2022; 14(23): 5155. CrossRef
From fecal microbiota transplantation toward next-generation beneficial microbes: The case of Anaerobutyricum soehngenii
Koen Wortelboer, Annefleur M. Koopen, Hilde Herrema, Willem M. de Vos, Max Nieuwdorp, E. Marleen Kemper
Frontiers in Medicine.2022;[Epub] CrossRef
Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells
Leena Hilakivi-Clarke, Vivek Verma, Maddie McDermott, Pal Koak, Fabia de Oliveira Andrade
Frontiers in Microbiomes.2022;[Epub] CrossRef
La microbiota intestinal en la salud y en la enfermedad
M.Á. Ortega, C. García-Montero, O. Fraile-Martínez, J. Monserrat, M.A. Álvarez-Mon
Medicine - Programa de Formación Médica Continuada Acreditado.2022; 13(69): 4054. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.